Table 5.

VEGFR-2 and EGFR inhibitory properties of the synthesized conjugates and 5-fluorouracil in MCF7 (breast) and HCT116 (colon) cancer cell lines.

Entry	Compd.	VEGFR2				EGFR
		MCF7		HCT116		MCF7		HCT116
		RQ	% Inhibition	RQ	% Inhibition	RQ	% Inhibition	RQ	% Inhibition
1	Control	3.725	---	3.817	---	4.226	---	4.0382	---
2	5a	1.32	64.6	1.24	67.5	0.41	90.3	1.24	69.3
3	5b	1.6	57.0	1.11	70.9	0.69	83.7	1.1	72.8
4	5c	1.51	59.5	1.02	73.3	0.61	85.6	1.5	62.9
5	5d	1.91	48.7	1.5	60.7	1.52	64.0	1.377	65.9
6	5e	2.202	40.9	2.209	42.1	1.707	59.6	1.664	58.8
7	5f	1.56	58.1	1.37	64.1	1	76.3	1.516	62.5
8	5 g	2.324	37.6	2.393	37.3	1.638	61.2	1.554	61.5
9	5 h	2.032	45.4	2.398	37.2	1.737	58.9	1.698	57.9
10	5i	2.000	46.3	2.297	39.8	1.540	63.6	1.564	61.3
11	5j	1.9	49.0	0.8	79.0	1.45	65.7	1.273	68.5
12	5 k	1.5	59.7	1.2	68.6	1.31	69.0	1.479	63.4
13	5 l	1.1	70.5	0.9	76.4	1.4	66.9	1.336	66.9
14	5 m	1.966	47.2	1.13	70.4	1.59	62.4	1.273	68.5
15	5n	2.338	37.2	2.389	37.4	1.825	56.8	1.610	60.1
16	5o	1.38	63.0	1.16	69.6	1.3	69.2	1.283	68.2
17	5p	2.209	40.7	2.304	39.6	1.731	59.0	1.763	56.3
18	5-FU	1.22	67.2	0.94	75.4	0.6	85.8	0.76	81.2

RQ = Relative quantification